GAMMA Investing LLC Purchases Shares of 2,755 GSK plc (NYSE:GSK)

GAMMA Investing LLC acquired a new stake in shares of GSK plc (NYSE:GSK) in the 4th quarter, HoldingsChannel reports. The fund acquired 2,755 shares of the pharmaceutical company’s stock, valued at approximately $109,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of GSK. FMR LLC grew its holdings in GSK by 7.7% in the third quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after purchasing an additional 1,291,161 shares during the period. Kahn Brothers Group Inc. bought a new stake in GSK in the 3rd quarter valued at $46,483,000. Adage Capital Partners GP L.L.C. purchased a new stake in GSK in the 3rd quarter worth $45,114,000. Morningstar Investment Services LLC lifted its stake in GSK by 1,684.1% in the 3rd quarter. Morningstar Investment Services LLC now owns 1,136,495 shares of the pharmaceutical company’s stock worth $41,300,000 after purchasing an additional 1,072,792 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in shares of GSK in the 3rd quarter worth about $25,625,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

NYSE:GSK opened at $41.11 on Monday. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. The company’s 50-day moving average price is $41.83 and its 200-day moving average price is $38.97. GSK plc has a twelve month low of $33.33 and a twelve month high of $43.84. The company has a market cap of $85.20 billion, a P/E ratio of 13.66, a P/E/G ratio of 1.44 and a beta of 0.64.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The company had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. On average, sell-side analysts forecast that GSK plc will post 4.03 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were given a dividend of $0.3564 per share. This represents a $1.43 annualized dividend and a dividend yield of 3.47%. The ex-dividend date was Thursday, February 22nd. This is an increase from GSK’s previous quarterly dividend of $0.34. GSK’s payout ratio is currently 52.82%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on GSK shares. Morgan Stanley began coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Finally, Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.